Kinetic analysis and evaluation of the mechanisms involved in the resolution of experimental nontypeable Haemophilus influenzae-induced otitis media after transcutaneous immunization

Vaccine

Volumn 31, Issue 34, 2013, Pages 3417-3426

  Novotny, Laura A ^a   Clements, John D ^b   Bakaletz, Lauren O ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chimv4; Chinchilla; Dendritic cell; DmLT; Mucosal biofilm; OMP P5; Type IV pilus

Indexed keywords

GAMMA INTERFERON; HAEMOPHILUS INFLUENZAE VACCINE; INTERLEUKIN 17; OUTER MEMBRANE PROTEIN; OUTER MEMBRANE PROTEIN P5; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM CULTURE; CD4+ T LYMPHOCYTE; CHINCHILLA; DENDRITIC CELL; HAEMOPHILUS INFLUENZAE; IMMUNIZATION; KINETICS; MIDDLE EAR MUCOSA; NONHUMAN; NONTYPEABLE HAEMOPHILUS INFLUENZAE; OTITIS MEDIA; PRIORITY JOURNAL; TRANSCUTANEOUS IMMUNIZATION;

CHIMV4; CHINCHILLA; DENDRITIC CELL; DMLT; MUCOSAL BIOFILM; OMP P5; TYPE IV PILUS;

ADHESINS, BACTERIAL; ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ANIMALS; BACTERIAL ADHESION; BACTERIAL LOAD; BACTERIAL OUTER MEMBRANE PROTEINS; BIOFILMS; CD4-POSITIVE T-LYMPHOCYTES; CHINCHILLA; DENDRITIC CELLS; DERMIS; EAR, MIDDLE; HAEMOPHILUS INFECTIONS; HAEMOPHILUS INFLUENZAE; HAEMOPHILUS VACCINES; IMMUNIZATION; INTERFERON-GAMMA; INTERLEUKIN-17; OTITIS MEDIA;

EID: 84880514393     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.10.033     Document Type: Article

References (90)

1. Monasta L., Ronfani L., Marchetti F., Montico M., Vecchi Brumatti L., Bavcar A., et al. Burden of disease caused by otitis media: systematic review and global estimates. PLoS ONE 2012, 7(4):e36226.
2. Diagnosis and management of acute otitis media. Pediatrics 2004, 113(May (5)):1451-1465.
3. Baldwin R.L. Effects of otitis media on child development. Am J Otol 1993, 14(November (6)):601-604.
4. Johnson D.L., McCormick D.P., Baldwin C.D. Early middle ear effusion and language at age seven. J Commun Disord 2008, 41(January-February (1)):20-32.
5. McCormick D.P., Johnson D.L., Baldwin C.D. Early middle ear effusion and school achievement at age seven years. Ambul Pediatr 2006, 6(September-October (5)):280-287.
6. Hunter L.L., Margolis R.H., Giebink G.S. Identification of hearing loss in children with otitis media. Ann Otol Rhinol Laryngol Suppl 1994, 163(May):59-61.
7. Song J.H., Dagan R., Klugman K.P., Fritzell B. The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine 2012, 30(April (17)):2728-2737.
8. Leibovitz E., Broides A., Greenberg D., Newman N. Current management of pediatric acute otitis media. Expert Rev Anti Infect Ther 2010, 8(February (2)):151-161.
9. Bakaletz L.O., Baker B.D., Jurcisek J.A., Harrison A., Novotny L.A., Bookwalter J.E., et al. Demonstration of Type IV pilus expression and a twitching phenotype by Haemophilus influenzae. Infect Immun 2005, 73(March (3)):1635-1643.
10. Sirakova T., Kolattukudy P.E., Murwin D., Billy J., Leake E., Lim D., et al. Role of fimbriae expressed by nontypeable Haemophilus influenzae in pathogenesis of and protection against otitis media and relatedness of the fimbrin subunit to outer membrane protein A. Infect Immun 1994, 62(May (5)):2002-2020.
11. Jurcisek J.A., Bakaletz L.O. Biofilms formed by nontypeable Haemophilus influenzae in vivo contain both double-stranded DNA and type IV pilin protein. J Bacteriol 2007, 189(May (10)):3868-3875.
12. Jurcisek J.A., Bookwalter J.E., Baker B.D., Fernandez S., Novotny L.A., Munson R.S., et al. The PilA protein of non-typeable Haemophilus influenzae plays a role in biofilm formation, adherence to epithelial cells and colonization of the mammalian upper respiratory tract. Mol Microbiol 2007, 65(September (5)):1288-1299.
13. Novotny L.A., Adams L.D., Kang D.R., Wiet G.J., Cai X., Sethi S., et al. Epitope mapping immunodominant regions of the PilA protein of nontypeable Haemophilus influenzae (NTHI) to facilitate the design of two novel chimeric vaccine candidates. Vaccine 2009, 28(December (10)):279-289.
14. Bakaletz L.O., Leake E.R., Billy J.M., Kaumaya P.T. Relative immunogenicity and efficacy of two synthetic chimeric peptides of fimbrin as vaccinogens against nasopharyngeal colonization by nontypeable Haemophilus influenzae in the chinchilla. Vaccine 1997, 15(June (9)):955-961.
15. Novotny L.A., Jurcisek J.A., Pichichero M.E., Bakaletz L.O. Epitope mapping of the outer membrane protein P5-homologous fimbrin adhesin of nontypeable Haemophilus influenzae. Infect Immun 2000, 68(April (4)):2119-2128.
16. Novotny L.A., Pichichero M.E., Denoel P.A., Neyt C., Vanderschrick S., Dequesne G., et al. Detection and characterization of pediatric serum antibody to the OMP P5-homologous adhesin of nontypeable Haemophilus influenzae during acute otitis media. Vaccine 2002, 20(October (29-30)):3590-3597.
17. Novotny L.A., Bakaletz L.O. The fourth surface-exposed region of the outer membrane protein P5-homologous adhesin of nontypeable Haemophilus influenzae is an immunodominant but nonprotective decoying epitope. J Immunol 2003, 171(August (4)):1978-1983.
18. Summerton N.A., Welch R.W., Bondoc L., Yang H.H., Pleune B., Ramachandran N., et al. Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin. Vaccine 2010, 28(February (5)):1404-1411.
19. Norton E.B., Lawson L.B., Freytag L.C., Clements J.D. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol 2011, 18(April (4)):546-551.
20. Novotny L.A., Clements J.D., Bakaletz L.O. Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae. Mucosal Immunol 2011, 4(July (4)):456-467.
21. Giudice E.L., Campbell J.D. Needle-free vaccine delivery. Adv Drug Deliv Rev 2006, 58(April (1)):68-89.
22. Warger T., Schild H., Rechtsteiner G. Initiation of adaptive immune responses by transcutaneous immunization. Immunol Lett 2007, 109(March (1)):13-20.
23. Kenney R.T., Frech S.A., Muenz L.R., Villar C.P., Glenn G.M. Dose sparing with intradermal injection of influenza vaccine. N Engl J Med 2004, 351(November (22)):2295-2301.
24. Mishra D., Mishra P.K., Dubey V., Nahar M., Dabadghao S., Jain N.K. Systemic and mucosal immune response induced by transcutaneous immunization using Hepatitis B surface antigen-loaded modified liposomes. Eur J Pharm Sci 2008, 33(April (4-5)):424-433.
25. Lawson L.B., Clements J.D., Freytag L.C. Mucosal immune responses induced by transcutaneous vaccines. Curr Top Microbiol Immunol 2010, (November).
26. Glenn G.M., Scharton-Kersten T., Vassell R., Matyas G.R., Alving C.R. Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun 1999, 67(March (3)):1100-1106.
27. Russell M.W., Ogra P.L. Mucosal decisions: tolerance and responsiveness at mucosal surfaces. Immunol Invest 2010, 39(4-5):297-302.
28. Maeba S., Otake S., Namikoshi J., Shibata Y., Hayakawa M., Abiko Y., et al. Transcutaneous immunization with a 40-kDa outer membrane protein of Porphyromonas gingivalis induces specific antibodies which inhibit coaggregation by P. gingivalis. Vaccine 2005, 23(March (19)):2513-2521.
29. Belyakov I.M., Hammond S.A., Ahlers J.D., Glenn G.M., Berzofsky J.A. Transcutaneous immunization induces mucosal CTLs and protective immunity by migration of primed skin dendritic cells. J Clin Invest 2004, 113(April (7)):998-1007.
30. Vogt A., Mahe B., Costagliola D., Bonduelle O., Hadam S., Schaefer G., et al. Transcutaneous anti-influenza vaccination promotes both CD4 and CD8 T-cell immune responses in humans. J Immunol 2008, 180(February (3)):1482-1489.
31. Hansen S., Lehr C.M. Nanoparticles for transcutaneous vaccination. Microb Biotechnol 2012, 5(March (2)):156-167.
32. Skountzou I., Quan F.S., Jacob J., Compans R.W., Kang S.M. Transcutaneous immunization with inactivated influenza virus induces protective immune responses. Vaccine 2006, 24(August (35-36)):6110-6119.
33. Mawas F., Peyre M., Beignon A.S., Frost L., Del Giudice G., Rappuoli R., et al. Successful induction of protective antibody responses against Haemophilus influenzae type b and diphtheria after transcutaneous immunization with the glycoconjugate polyribosyl ribitol phosphate-cross-reacting material 197 vaccine. J Infect Dis 2004, 190(September (6)):1177-1182.
34. Hickey D.K., Aldwell F.E., Beagley K.W. Transcutaneous immunization with a novel lipid-based adjuvant protects against Chlamydia genital and respiratory infections. Vaccine 2009, 27(October (44)):6217-6225.
35. Naito S., Maeyama J., Mizukami T., Takahashi M., Hamaguchi I., Yamaguchi K. Transcutaneous immunization by merely prolonging the duration of antigen presence on the skin of mice induces a potent antigen-specific antibody response even in the absence of an adjuvant. Vaccine 2007, 25(December (52)):8762-8770.
36. Glenn G.M., Flyer D.C., Ellingsworth L.R., Frech S.A., Frerichs D.M., Seid R.C., et al. Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch. Expert Rev Vaccines 2007, 6(October (5)):809-819.
37. McKenzie R., Bourgeois A.L., Frech S.A., Flyer D.C., Bloom A., Kazempour K., et al. Transcutaneous immunization with the heat-labile toxin (LT) of enterotoxigenic Escherichia coli (ETEC): protective efficacy in a double-blind, placebo-controlled challenge study. Vaccine 2007, 25(May (18)):3684-3691.
38. Etchart N., Hennino A., Friede M., Dahel K., Dupouy M., Goujon-Henry C., et al. Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans. Vaccine 2007, 25(September (39-40)):6891-6899.
39. Hirobe S., Matsuo K., Quan Y.S., Kamiyama F., Morito H., Asada H., et al. Clinical study of transcutaneous vaccination using a hydrogel patch for tetanus and diphtheria. Vaccine 2012, 30(February (10)):1847-1854.
40. Frech S.A., Dupont H.L., Bourgeois A.L., McKenzie R., Belkind-Gerson J., Figueroa J.F., et al. Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial. Lancet 2008, 371(June (9629)):2019-2025.
41. Santegoets S.J., Gibbs S., Kroeze K., van de Ven R., Scheper R.J., Borrebaeck C.A., et al. Transcriptional profiling of human skin-resident Langerhans cells and CD1a+ dermal dendritic cells: differential activation states suggest distinct functions. J Leukoc Biol 2008, 84(July (1)):143-151.
42. Mathers A.R., Larregina A.T. Professional antigen-presenting cells of the skin. Immunol Res 2006, 36(1-3):127-136.
43. Kaplan D.H. In vivo function of Langerhans cells and dermal dendritic cells. Trends Immunol 2010, 31(December (12)):446-451.
44. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11(April (4 Suppl.)):S45-S53.
45. Czerkinsky C., Holmgren J. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr Top Microbiol Immunol 2010, (November (354)):1-18.
46. Wu H.Y., Russell M.W. Nasal lymphoid tissue, intranasal immunization, and compartmentalization of the common mucosal immune system. Immunol Res 1997, 16(2):187-201.
47. Jurcisek J.A., Durbin J.E., Kusewitt D.F., Bakaletz L.O. Anatomy of the nasal cavity in the chinchilla. Cells Tissues Organs 2003, 174(3):136-152.
48. Murphy T.F., Bakaletz L.O., Smeesters P.R. Microbial interactions in the respiratory tract. Pediatr Infect Dis J 2009, 28(October (10 Suppl.)):S121-S126.
49. Hall-Stoodley L., Hu F.Z., Gieseke A., Nistico L., Nguyen D., Hayes J., et al. Direct detection of bacterial biofilms on the middle-ear mucosa of children with chronic otitis media. JAMA 2006, 296(July (2)):202-211.
50. Martinez-Becerra F.J., Kissmann J.M., Diaz-McNair J., Choudhari S.P., Quick A.M., Mellado-Sanchez G., et al. Broadly protective Shigella vaccine based on type III secretion apparatus proteins. Infect Immun 2012, 80(March (3)):1222-1231.
51. Bakaletz L.O., Kennedy B.J., Novotny L.A., Duquesne G., Cohen J., Lobet Y. Protection against development of otitis media induced by nontypeable Haemophilus influenzae by both active and passive immunization in a chinchilla model of virus-bacterium superinfection. Infect Immun 1999, 67(June (6)):2746-2762.
52. Kennedy B.J., Novotny L.A., Jurcisek J.A., Lobet Y., Bakaletz L.O. Passive transfer of antiserum specific for immunogens derived from a nontypeable Haemophilus influenzae adhesin and lipoprotein D prevents otitis media after heterologous challenge. Infect Immun 2000, 68(May (5)):2756-2765.
53. Novotny L.A., Jurcisek J.A., Godfroid F., Poolman J.T., Denoel P.A., Bakaletz L.O. Passive immunization with human anti-protein D antibodies induced by polysaccharide protein D conjugates protects chinchillas against otitis media after intranasal challenge with Haemophilus influenzae. Vaccine 2006, 24(May (22)):4804-4811.
54. Kyd J.M., Cripps A.W., Novotny L.A., Bakaletz L.O. Efficacy of the 26-kilodalton outer membrane protein and two P5 fimbrin-derived immunogens to induce clearance of nontypeable Haemophilus influenzae from the rat middle ear and lungs as well as from the chinchilla middle ear and nasopharynx. Infect Immun 2003, 71(Aug (8)):4691-4699.
55. Mason K.M., Munson R.S., Bakaletz L.O. A mutation in the sap operon attenuates survival of nontypeable Haemophilus influenzae in a chinchilla model of otitis media. Infect Immun 2005, 73(January (1)):599-608.
56. Johnson R.W., McGillivary G., Denoel P., Poolman J., Bakaletz L.O. Abrogation of nontypeable Haemophilus influenzae Protein D function reduces phosphorylcholine decoration, adherence to airway epithelial cells, and fitness in a chinchilla model of otitis media. Vaccine 2010, 29(February(6)):1211-1221.
57. Krishnamurthy A., McGrath J., Cripps A.W., Kyd J.M. The incidence of Streptococcus pneumoniae otitis media is affected by the polymicrobial environment particularly Moraxella catarrhalis in a mouse nasal colonisation model. Microbes Infect 2009, 11(April (5)):545-553.
58. Hong W., Mason K., Jurcisek J., Novotny L., Bakaletz L.O., Swords W.E. Phosphorylcholine decreases early inflammation and promotes the establishment of stable biofilm communities of nontypeable Haemophilus influenzae strain 86-028NP in a chinchilla model of otitis media. Infect Immun 2007, 75(February (2)):958-965.
59. Goodman S.D., Obergfell K.P., Jurcisek J.A., Novotny L.A., Downey J.S., Ayala E.A., et al. Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-associated proteins. Mucosal Immunol 2011, 4(November (6)):625-637.
60. McGillivary G., Mason K.M., Jurcisek J.A., Peeples M.E., Bakaletz L.O. Respiratory syncytial virus-induced dysregulation of expression of a mucosal beta-defensin augments colonization of the upper airway by non-typeable Haemophilus influenzae. Cell Microbiol 2009, 11(September (9)):1399-1408.
61. Stoitzner P., Zanella M., Ortner U., Lukas M., Tagwerker A., Janke K., et al. Migration of langerhans cells and dermal dendritic cells in skin organ cultures: augmentation by TNF-alpha and IL-1beta. J Leukoc Biol 1999, 66(September (3)):462-470.
62. Harris R.H., Wilk D., Bevins C.L., Munson R.S., Bakaletz L.O. Identification and characterization of a mucosal antimicrobial peptide expressed by the chinchilla (Chinchilla lanigera) airway. J Biol Chem 2004, 279(May (19)):20250-20256.
63. Lim D.J., Chun Y.M., Lee H.Y., Moon S.K., Chang K.H., Li J.D., et al. Cell biology of tubotympanum in relation to pathogenesis of otitis media - a review. Vaccine 2000, 19(December (Suppl. 1)):S17-S25.
64. Taub D.D., Conlon K., Lloyd A.R., Oppenheim J.J., Kelvin D.J. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. Science 1993, 260(April (5106)):355-358.
65. Schall T.J., Bacon K., Camp R.D., Kaspari J.W., Goeddel D.V. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med 1993, 177(June (6)):1821-1826.
66. Morelli A.E., Rubin J.P., Erdos G., Tkacheva O.A., Mathers A.R., Zahorchak A.F., et al. CD4+ T cell responses elicited by different subsets of human skin migratory dendritic cells. J Immunol 2005, 175(December (12)):7905-7915.
67. Murphy T.F., Kirkham C. Biofilm formation by nontypeable Haemophilus influenzae: strain variability, outer membrane antigen expression and role of pili. BMC Microbiol 2002 Apr, 15(2):7.
68. Flemming H.C., Wingender J. The biofilm matrix. Nat Rev Microbiol 2010, 8(September (9)):623-633.
69. Starner T.D., Shrout J.D., Parsek M.R., Appelbaum P.C., Kim G. Subinhibitory concentrations of azithromycin decrease nontypeable Haemophilus influenzae biofilm formation and diminish established biofilms. Antimicrob Agents Chemother 2008, 52(January (1)):137-145.
70. Slinger R., Chan F., Ferris W., Yeung S.W., St Denis M., Gaboury I., et al. Multiple combination antibiotic susceptibility testing of nontypeable Haemophilus influenzae biofilms. Diagn Microbiol Infect Dis 2006, 56(November (3)):247-253.
71. Gallaher T.K., Wu S., Webster P., Aguilera R. Identification of biofilm proteins in non-typeable Haemophilus influenzae. BMC Microbiol 2006, 6:65.
72. Vesa S., Kleemola M., Blomqvist S., Takala A., Kilpi T., Hovi T. Epidemiology of documented viral respiratory infections and acute otitis media in a cohort of children followed from two to twenty-four months of age. Pediatr Infect Dis J 2001, 20(June (6)):574-581.
73. Suzuki K., Bakaletz L.O. Synergistic effect of adenovirus type 1 and nontypeable Haemophilus influenzae in a chinchilla model of experimental otitis media. Infect Immun 1994, 62(May (5)):1710-1718.
74. Brockson M.E., Novotny L.A., Jurcisek J.A., McGillivary G., Bowers M.R., Bakaletz L.O. Respiratory syncytial virus promotes Moraxella catarrhalis-induced ascending experimental otitis media. PLoS ONE 2012, 7(6):e40088.
75. Giebink G.S., Berzins I.K., Marker S.C., Schiffman G. Experimental otitis media after nasal inoculation of Streptococcus pneumoniae and influenza A virus in chinchillas. Infect Immun 1980, 30(November (2)):445-450.
76. Prymula R., Peeters P., Chrobok V., Kriz P., Novakova E., Kaliskova E., et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typeable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 2006, 367(March (9512)):740-748.
77. Ehrlich G.D., Veeh R., Wang X., Costerton J.W., Hayes J.D., Hu F.Z., et al. Mucosal biofilm formation on middle-ear mucosa in the chinchilla model of otitis media. JAMA 2002, 287(April (13)):1710-1715.
78. Pang B., Hong W., Kock N.D., Swords W.E. Dps promotes survival of nontypeable Haemophilus influenzae in biofilm communities in vitro and resistance to clearance in vivo. Front Cell Infect Microbiol 2012, 2:58.
79. Bouchet V., Hood D.W., Li J., Brisson J.R., Randle G.A., Martin A., et al. Host-derived sialic acid is incorporated into Haemophilus influenzae lipopolysaccharide and is a major virulence factor in experimental otitis media. Proc Natl Acad Sci U.S.A. 2003, 100(July (15)):8898-8903.
80. Leroy M., Cabral H., Figueira M., Bouchet V., Huot H., Ram S., et al. Multiple consecutive lavage samplings reveal greater burden of disease and provide direct access to the nontypeable Haemophilus influenzae biofilm in experimental otitis media. Infect Immun 2007, 75(August (8)):4158-4172.
81. Daines D.A., Bothwell M., Furrer J., Unrath W., Nelson K., Jarisch J., et al. Haemophilus influenzae luxS mutants form a biofilm and have increased virulence. Microb Pathog 2005, 39(September (3)):87-96.
82. Greiner L.L., Watanabe H., Phillips N.J., Shao J., Morgan A., Zaleski A., et al. Nontypeable Haemophilus influenzae strain 2019 produces a biofilm containing N-acetylneuraminic acid that may mimic sialylated O-linked glycans. Infect Immun 2004, 72(July (7)):4249-4260.
83. Jurcisek J., Greiner L., Watanabe H., Zaleski A., Apicella M.A., Bakaletz L.O. Role of sialic acid and complex carbohydrate biosynthesis in biofilm formation by nontypeable Haemophilus influenzae in the chinchilla middle ear. Infect Immun 2005, 73(June (6)):3210-3218.
84. Weimer K.E., Armbruster C.E., Juneau R.A., Hong W., Pang B., Swords W.E. Coinfection with Haemophilus influenzae promotes pneumococcal biofilm formation during experimental otitis media and impedes the progression of pneumococcal disease. J Infect Dis 2010, 202(October (7)):1068-1075.
85. Hong W., Pang B., West-Barnette S., Swords W.E. Phosphorylcholine expression by nontypeable Haemophilus influenzae correlates with maturation of biofilm communities in vitro and in vivo. J Bacteriol 2007, 189(November (22)):8300-8307.
86. Freytag L.C., Clements J.D. Mucosal adjuvants. Vaccine 2005, 23(15):1804-1813.
87. Pazgier M., Hoover D.M., Yang D., Lu W., Lubkowski J. Human beta-defensins. Cell Mol Life Sci 2006, 63(June (11)):1294-1313.
88. Dhople V., Krukemeyer A., Ramamoorthy A. The human beta-defensin-3, an antibacterial peptide with multiple biological functions. Biochim Biophys Acta 2006, 1758(September (9)):1499-1512.
89. Rohrl J., Yang D., Oppenheim J.J., Hehlgans T. Human beta-defensin 2 and 3 and their mouse orthologs induce chemotaxis through interaction with CCR2. J Immunol 2010, 184(June (12)):6688-6694.
90. Nagaoka I., Niyonsaba F., Tsutsumi-Ishii Y., Tamura H., Hirata M. Evaluation of the effect of human beta-defensins on neutrophil apoptosis. Int Immunol 2008, 20(April (4)):543-553.